Somatuline Predictive Factors in Acromegaly and NET

Ipsen156 enrolled

Overview

The aim of the study is to identify predictive factors for the response to Lanreotide treatment in Acromegaly as well as in Neuroendocrine Tumours.

Study Type

OBSERVATIONAL

Enrollment

156

Conditions

Acromegaly Neuroendocrine Tumours

Interventions

Somatuline Autogel® 60, 90 or 120 mgDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Written informed consent (also mandatory in case of retrospective documentation of subject data) * Diagnosis of acromegaly or NET with the intention to be treated with ATG or already on treatment with ATG Exclusion Criteria: * The subject has already been included in this study * Participation in an interventional trial

Locations (3)

University Hospital of Vienna

Vienna, Austria

ENDOC

Hamburg, Germany

University Hospital Basel

Basel, Switzerland

Outcomes

Primary Outcomes

Change in biochemical markers (Growth Hormone [GH] & Insulin-like Growth Factor 1 [IGF-1] in acromegaly subjects and Chromogranin A [CgA] in NET subjects)

Time frame: Baseline and 1 year

Secondary Outcomes

Change in biochemical markers (Growth Hormone [GH] & Insulin-like Growth Factor 1 [IGF-1] in acromegaly subjects and Chromogranin A [CgA] in NET subjects)

Time frame: Baseline and 2 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.